CDER published draft guidance on submitting controlled correspondence to FDA requesting information related to generic drug development. Background and commenting information is provided in the Federal Register announcement.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
